Flutisal

Flutisal

Dry Powder Inhalation Capsule (DPI)

🧬 Salmeterol + Fluticasone Propionate 🏢 Incepta Pharmaceuticals Ltd.
Generic Name Salmeterol + Fluticasone Propionate
Manufacturer Incepta Pharmaceuticals Ltd.
Unit Price Unit Price: ৳ 5.00 (5 x 6: ৳ 150.00) Strip Price: ৳ 30.00

🔹 Indications

Flutisal is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
  • Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
  • Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.

🔹 Pharmacology

Flutisal is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
  • Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
  • Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.

🔹 Dosage & Administration

Flutisal is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
  • Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
  • Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.

🔹 Interaction

Flutisal is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
  • Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
  • Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.

🔹 Contraindications

Flutisal is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
  • Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
  • Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.

🔹 Side Effects

Flutisal is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
  • Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
  • Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.

🔹 Pregnancy & Lactation

Flutisal is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
  • Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
  • Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.

🔹 Precautions & Warnings

Flutisal is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
  • Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
  • Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.

🔹 Pediatric Usage

Flutisal is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
  • Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
  • Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.

🔹 Storage Conditions

Flutisal is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate:
  • Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting β2-agonist or
  • Patients already adequately controlled on both inhaled corticosteroid and long-acting β2-agonist.

💡 Frequently Asked Questions

Flutisal is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate: Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled s...
Flutisal is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate: Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled s...
Flutisal is indicated in the regular treatment of asthma where use of a combination product (long-acting β2-agonist and inhaled corticosteroid) is appropriate: Patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled s...

User Reviews

No reviews yet!
Be the first to share your experience.

Write a Review